« Back
Human iPSC-derived hepatocytes and cardiomyocytes for drug toxicity testing
Human iPSC-derived hepatocytes and cardiomyocytes for drug toxicity testing
Submitted on 30 Mar 2015

AnnandRR; Vardaro R; Hamilton B; Akakira R; Tamura K; Yoshida S; Lin YC; Toyoda D; Kogami H; Okuda Y; Watanabe T; Inamura M
ReproCELL, Inc.
This poster was presented at SOT 2015
Poster Views: 1,189
View poster »
Poster Abstract
Pharmaceutical candidate compounds require an extended period of time and high development costs before reaching the market. However, for various reasons, a high number of the candidate compounds are eliminated in the development process. The candidate compound elimination is frequently based on hepatotoxicity and cardiotoxicity. Although human primary cells are widely used for drug toxicity testing, they have posed issues such as lot-to-lot variation. Moreover, it is difficult to perform long-term tests with the same donor when using human primary cells due to the limited supply.
Human iPSC-derived hepatocytes ReproHepato™ cells were cultivated on 96-well plates, and the cells were exposed to five representative toxic compounds: acetaminophen, amiodarone, cyclophosphamide, diclofenac, and flutamide. Using conventional assays to measure ATP and LDH, we observed dose-dependent toxicity, and each compound showed IC50 values similar to the cytotoxicity observed using primary human hepatocytes (PHHs). Furthermore, we also observed toxicity using high content analysis, which simultaneously measures cell number, reduction in glutathione level, active oxygen, and mitochondrial membrane potential. These results show that ReproHepato can be used as an alternative to PHHs for routine cytotoxicity testing.
We cultivated Human iPSC-derived cardiomyocytes ReproCardio 2™ cells on 96-well plates, and exposed the cells to five representative toxic compounds: aspirin, verapamil, isoproterenol, E-4031 and flecainide. Upon the addition of chemical compounds, the prolongation or reduction of the field potential duration was observed in a Multi-Electrode Array (MEA) experiment, with small lot-to-lot variation. These results demonstrate that ReproCardio 2 is a suitable model system for in vitro cardiotoxicity screening for QT prolongation and arrhythmia potential.
In summary, human iPSC-derived hepatocytes and cardiomyocytes can be used for drug toxicity testing, as alternative sources of human primary cells.
Report abuse »
Ask the author a question about this poster.
Ask a Question »

Creative Commons

Related Posters

Unique Users-Initiated Biotransformation Reactions for Analysis of Xenobiotic Metabolism
Richard Lee, Rytis Kubilius, Vitaly Lashin, Alexandr Sakharov, Anne Marie Smith

Screening of Common Spices Against Multi-Drug Resistant Mycobacterium tuberculosis
Swati Singh1, Arpita Batta1,2,  Maria Kulsoom1, T. N. Dhole2, B. N. Mishra1, Vineeta Singh1

Arrayed synthetic CRISPR libraries are a powerful resource for gene knockout or gene activation screening
Žaklina Strezoska, Hidevaldo Machado, Matthew Perkett, Eldon Chou, Elena Maksimova, Emily Anderson, Maren Gross, Anja Smith

New BIONET Compounds for CNS Diseases
Steve Brough1, Andrew Lowerson1 and Nikolay T. Tzvetkov2

High-throughput Carbonic Anhydrase Activity and Inhibitor Screening Assays
Suratna Hazra, Ph.D., Grigoriy Tchaga, Ph.D., and Gordon Yan, Ph.D.